<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04973943</url>
  </required_header>
  <id_info>
    <org_study_id>FreeDNA-CAR</org_study_id>
    <nct_id>NCT04973943</nct_id>
  </id_info>
  <brief_title>Donor-derived Cell Free DNA as a New Biomarker in Cardiac Acute Rejection</brief_title>
  <acronym>FreeDNA-CAR</acronym>
  <official_title>Donor-derived Cell Free DNA as a Potential New Biomarker in Cardiac Transplantation: Role in Acute Rejection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Puerta de Hierro University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Puerta de Hierro University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      FreeDNA-CAR is a prospective, observational multicenter study, that will include a total of&#xD;
      200 adult heart transplant (HT) patients from 14 centers in Spain. Our main objective is to&#xD;
      test donor-derived Cell-Free DNA (dd-cfDNA) against endomyocardial biopsy (EMB) for the&#xD;
      diagnosis of acute cellular rejection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients will be enrolled immediately after HT, and will undergo undergo routine&#xD;
      surveillance EMB at 15 days, 1 month, 2, 3, 4, 6 and 12 months after HT. Simultaneously with&#xD;
      each EMB, dd-cfDNA will be measured in plasma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 19, 2019</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Association between dd-cfDNA levels and the presence of acute cellular rejection</measure>
    <time_frame>1 year</time_frame>
    <description>Association between dd-cfDNA levels above a certain cut-point and the presence of treatable acute cellular rejection as determined by endomyocardial biopsy (graded by International Society of Heart and Lung Transplantation 2010 classification, grade &gt; 1R).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under curve for dd-cfDNA</measure>
    <time_frame>1 year</time_frame>
    <description>To define a cutt-off point of dd-cfDNA level with a high negative predictive value that could obviate the need to perform surveillance endomyocardial biopsies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between dd-cfDNA and antibody mediated rejection (AMR)</measure>
    <time_frame>1 year</time_frame>
    <description>Correlation between dd-cfDNA and antibody mediated rejection (AMR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between dd-cfDNA and immunosuppressive (IS) treatment</measure>
    <time_frame>1 year</time_frame>
    <description>Subanalysis of association between dd-cfDNA and rejection stratified by IS regimen (type and dose of drug).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between dd-cfDNA (%) and left ventricular ejection fraction</measure>
    <time_frame>1 year</time_frame>
    <description>Association between dd-cfDNA and left ventricular ejection fraction (LVEF). All echocardiograms will be performed on the same day of EMB.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the biomarker's kinetics at 15 days post-transplant</measure>
    <time_frame>15 days</time_frame>
    <description>Determine dd-cfDNA levels at 15 days post-transplant in absence of rejection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between dd-cfDNA levels and cytomegalovirus (CMV) infection</measure>
    <time_frame>1 year</time_frame>
    <description>Association between dd-cfDNA levels and CMV infection as determined by CMV polymerase chain reaction (number of copies per ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine a cut-off point of dd-cfDNA that allows to differentiate between acute cellular rejection (ACR) and antibody mediated rejection (AMR)</measure>
    <time_frame>1 year</time_frame>
    <description>Determine a cut-off point of dd-cfDNA that allows to differentiate between acute cellular rejection (ACR) and antibody mediated rejection (AMR)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Heart Transplant Rejection</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Donor-derived cell Free DNA</intervention_name>
    <description>Measurement of dd-cfDNA and comparison against grade of rejection as determined by endomyocardial biopsy, taken simultaneously</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Heart transplant recipients aged 18 and over&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients &gt; 18 years old who undergo heart transplant during the recruiting period&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with moderate or severe Primary Graft Dysfunction&#xD;
&#xD;
          -  Patients on invasive mechanical ventilation 15 days after heart transplant&#xD;
&#xD;
          -  Patients on renal replacement therapy, continuous or periodic, 15 days after heart&#xD;
             transplant&#xD;
&#xD;
          -  Heart Transplant due to a cardiomyopathy that could potentially recur on the graft&#xD;
             (cardiac amyloidosis, Chagas disease or sarcoidosis, amongst others)&#xD;
&#xD;
          -  Multiorgan transplant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marta B Jimenez-Blanco Bravo, MD</last_name>
    <phone>0034 637747916</phone>
    <email>martajbb@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Javier Segovia Cubero, MD PhD</last_name>
    <email>jsecu@telefonica.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33011</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Puerta de Hierro</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Jimenez-Blanco Bravo, MD</last_name>
      <phone>0034637747916</phone>
      <email>martajbb@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Javier Segovia Cubero, MD PhD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Clinica Universitaria de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario A Coru침a</name>
      <address>
        <city>A Coru침a</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital 12 octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Gregorio Mara침칩n</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Arrixaca</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital La Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 15, 2021</study_first_submitted>
  <study_first_submitted_qc>July 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2021</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Puerta de Hierro University Hospital</investigator_affiliation>
    <investigator_full_name>Javier Segovia Cubero</investigator_full_name>
    <investigator_title>Head of Cardiology Department</investigator_title>
  </responsible_party>
  <keyword>Donor-derived cell Free DNA</keyword>
  <keyword>Acute cellular rejection</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

